港股异动 | 君实生物(01877)现涨近5% JS001sc肺癌III期临床达主要终点公司近期将递交上市许可申请

智通财经11-25

智通财经APP获悉，君实生物(01877)现涨近5%，截至发稿，涨4.71%，报24.92港元，成交额3254.28万港元。

消息面上，君实生物宣布，由公司自主研发的特瑞普利单抗注射液(皮下注射)(产品代号：JS001sc)对比特瑞普利单抗注射液(产品代号：JS001)联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌(NSCLC)的多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产品的上市许可申请。

公告显示，JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂，为首款进入III期临床研究阶段的国产抗PD-1单抗皮下制剂，有望给患者带来用药的便捷性。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2586540410?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-25 10:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586540410","market":"sh","top_or_hot":-1,"title":"港股异动 | 君实生物(01877)现涨近5% JS001sc肺癌III期临床达主要终点 公司近期将递交上市许可申请","media":"智通财经","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/688180\">君实生物</a>(01877)现涨近5%，截至发稿，涨4.71%，报24.92港元，成交额3254.28万港元。</p><p>消息面上，<a href=\"https://laohu8.com/S/01877\">君实生物</a>宣布，由公司自主研发的特瑞<a href=\"https://laohu8.com/S/300630\">普利</a>单抗注射液(皮下注射)(产品代号：JS001sc)对比特瑞普利单抗注射液(产品代号：JS001)联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌(NSCLC)的多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产品的上市许可申请。</p><p>公告显示，JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂，为首款进入III期临床研究阶段的国产抗PD-1单抗皮下制剂，有望给患者带来用药的便捷性。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 君实生物(01877)现涨近5% JS001sc肺癌III期临床达主要终点 公司近期将递交上市许可申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 君实生物(01877)现涨近5% JS001sc肺癌III期临床达主要终点 公司近期将递交上市许可申请\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2025-11-25 10:21</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/688180\">君实生物</a>(01877)现涨近5%，截至发稿，涨4.71%，报24.92港元，成交额3254.28万港元。</p><p>消息面上，<a href=\"https://laohu8.com/S/01877\">君实生物</a>宣布，由公司自主研发的特瑞<a href=\"https://laohu8.com/S/300630\">普利</a>单抗注射液(皮下注射)(产品代号：JS001sc)对比特瑞普利单抗注射液(产品代号：JS001)联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌(NSCLC)的多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产品的上市许可申请。</p><p>公告显示，JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂，为首款进入III期临床研究阶段的国产抗PD-1单抗皮下制剂，有望给患者带来用药的便捷性。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1373109.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1373109.html","article_id":"2586540410","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586540410","pubTimestamp":1764037296,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，君实生物宣布，由公司自主研发的特瑞普利单抗注射液对比特瑞普利单抗注射液联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌的多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产品的上市许可申请。公告显示，JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂，为首款进入III期临床研究阶段的国产抗PD-1单抗皮下制剂，有望给患者带来用药的便捷性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","III":"信息服务","BK1161":"生物科技","BK1583":"高瓴概念","BK4134":"信息科技咨询与其它服务","BK0239":"医药制造","01877":"君实生物","BK1515":"抗疫概念"},"translate_title":"Changes in Hong Kong stocks | Junshi Biotech (01877) is now up nearly 5% JS001sc lung cancer phase III clinical trials have reached the primary endpoint. The company will submit a marketing authorization application in the near future","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":1.5,"III":1.5,"01877":1.5},"content_text":"智通财经APP获悉，君实生物(01877)现涨近5%，截至发稿，涨4.71%，报24.92港元，成交额3254.28万港元。消息面上，君实生物宣布，由公司自主研发的特瑞普利单抗注射液(皮下注射)(产品代号：JS001sc)对比特瑞普利单抗注射液(产品代号：JS001)联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌(NSCLC)的多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产品的上市许可申请。公告显示，JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂，为首款进入III期临床研究阶段的国产抗PD-1单抗皮下制剂，有望给患者带来用药的便捷性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586540410","isCrawlerRequest":true}

港股异动 | 君实生物(01877)现涨近5% JS001sc肺癌III期临床达主要终点 公司近期将递交上市许可申请

精彩评论

港股异动 | 君实生物(01877)现涨近5% JS001sc肺癌III期临床达主要终点公司近期将递交上市许可申请